Related Experiment Video
Updated: Dec 21, 2025
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Azacitidine-associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report
Takeshi Hagino1, Wataru Shinomiya2, Hiroko Hidai1
1Department of Hematology, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan.
What Is Known And Objective:
5-Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS).
Case Description:
We herein report an 83-year-old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA.
What Is New And Conclusion:
We herein report as-yet-undescribed potential side effects, AZA-associated haemorrhagic enteritis that should be kept in mind.
